A recent retrospective multicenter chart review in Germany observed a reduction in seizure frequency and sustained treatment retention for up to 12 months across different age groups, among patients with severe, treatment-refractory LGS or DS receiving adjunctive CBD and clobazam simultaneously [146]. This evidence concerns the gene OPN1MW and Dravet syndrome.